Legend Biotech Full Year 2024 Earnings: Beats Expectations

Simply Wall St · 6d ago

Legend Biotech (NASDAQ:LEGN) Full Year 2024 Results

Key Financial Results

  • Revenue: US$627.2m (up 120% from FY 2023).
  • Net loss: US$177.0m (loss narrowed by 66% from FY 2023).
  • US$0.97 loss per share (improved from US$2.94 loss in FY 2023).
earnings-and-revenue-growth
NasdaqGS:LEGN Earnings and Revenue Growth March 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Legend Biotech Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 32%.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 9.4% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Legend Biotech's balance sheet.